Eli Lilly
-
FDA approves once-daily oral GLP-1 for obesity treatment
The FDA has approved orforglipron, a once-daily oral GLP-1 receptor agonist, for adults with obesity, or with overweight plus at least one weight-related comorbidity. Eli…
The FDA has approved orforglipron, a once-daily oral GLP-1 receptor agonist, for adults with obesity, or with overweight plus at least one weight-related comorbidity. Eli…